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Abstract: Iron–manganese-doped sulfated zirconia nanoparticles with both Lewis and Brønsted 
acidic sites were prepared by a hydrothermal impregnation method followed by calcination at 
650°C for 5 hours, and their cytotoxicity properties against cancer cell lines were determined. 
The characterization was carried out using X-ray diffraction, thermogravimetric analysis, Fourier 
transform infrared spectroscopy, Brauner–Emmett–Teller (BET) surface area measurements, 
X-ray fluorescence, X-ray photoelectron spectroscopy, zeta size potential, and transmission 
electron microscopy (TEM). The cytotoxicity of iron–manganese-doped sulfated zirconia nano-
particles was determined using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) assays against three human cancer cell lines (breast cancer MDA-MB231 cells, colon 
carcinoma HT29 cells, and hepatocellular carcinoma HepG2 cells) and two normal human 
cell lines (normal hepatocyte Chang cells and normal human umbilical vein endothelial cells 
[HUVECs]). The results suggest for the first time that iron–manganese-doped sulfated zirconia 
nanoparticles are cytotoxic to MDA-MB231 and HepG2 cancer cells but have less toxicity to 
HT29 and normal cells at concentrations from 7.8 μg/mL to 500 μg/mL. The morphology of 
the treated cells was also studied, and the results supported those from the cytotoxicity study 
in that the nanoparticle-treated HepG2 and MDA-MB231 cells had more dramatic changes in 
cell morphology than the HT29 cells. In this manner, this study provides the first evidence that 
iron–manganese-doped sulfated zirconia nanoparticles should be further studied for a wide range 
of cancer applications without detrimental effects on healthy cell functions.
Keywords: nanopartices, Lewis and Brønsted acidic sites, anticancer applications, HT29 cells, 
transition metal oxide
Introduction
Many processes which are very significant to life (such as pharmaceutical and 
petrochemical processes) have benefited from solid acid enhancers leading to improve-
ments in selectivity and activity.1,2 It has been reported that the status of active sites 
on a material surface, whether it is of Brønsted or Lewis nature, are common factors 
for promoting bioactivity and bioselectivity. In this respect, the incorporation of pow-
erful acidic anions on the surface of various material supporting structures (such as 
alumina, silica, and zirconia) has attracted great attention.3 Among the most powerful 
acidic anions, sulfate species doped on the surface of zirconium oxide have gener-
ated great potential for a number of significant processes such as organic synthesis.4 
Nevertheless, the selectivity and activity of nanoparticles of iron(+3)–manganese-doped 
sulfated zirconia can be governed by the effective incorporation of ferric oxide and 
manganese dioxide as well as sulfate anions into the zirconia skeleton.5 They display 
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the best catalytic activity toward n-butane isomerization 
under reasonable conditions.6
Along the same lines, nanoparticle medications have 
arisen as a modern research direction for the release of 
hydrophobic medicines owing to their characteristic gains 
over colloidal drug transporters.7 Generally, transition metal 
oxides have been commonly employed either as supporters 
or as promoters to improve physiochemical properties for 
many reactions.8–11 For example, approximately all advanced 
materials contain an oxide as the active system which shows 
both hydrogen ion and electron transmission abilities and 
should be utilized as an enhancer in acid–base reactions as 
well as electron gain and release reactions. These reduction–
oxidation processes utilizing metal oxide redox properties 
have been widely applied as an environmentally friendly 
process for the full oxidation of polluted ingredients.12–19
Moreover, transition metal oxide systems having redox 
properties are also used for the conversion of organic 
constituent sustainable and renewable chemicals.20–22 The 
physicochemical properties of transition metal oxides are 
considered to be a potential factor in carrying out discriminat-
ing organic reactions. Meanwhile, the rate-determining step 
on the surface of such novel materials would be evaluated 
via the mass of energetic sites in addition to the Brauner–
Emmett–Teller (BET) surface area with notable improve-
ments in catalytic activity related to increases in BET surface 
area that comes from smaller particle diameters. Thus, in the 
emerging field of nanoparticles, the synthesis of transition 
metal oxide nanoparticles has garnered significant consider-
ation, attributable to unique physical and chemical properties 
gained for materials at the nanoscale.23,24
The surface of zirconia is known to have all of these 
physicochemical properties. Doping ZrO
2
 with materials such 
as ferric, manganese, nickel, platinum, phosphate, and sulfate 
species has significantly improved its catalytic activity.25–27 
In particular, iron(+3)–manganese-doped sulfated zirconia 
has been commonly employed to enhance various life-
support operations.28–31 Additionally, these transition metal 
oxide materials have a promising future in various ecological 
decontamination applications such as for sustainable chemi-
cal as well as oncological drug applications.
Due to its magnetic properties, iron doping can also 
impact magnetic properties to aid in the directed treat-
ment of diseases through magnetic force. Moreover, the 
discovery of novel antitumor agents is largely based on 
the screening of cytotoxic activity against cancer cell lines 
in vitro.32,33 The therapeutic utilization of nanoparticles for 
cancer applications often starts via human cell culture testing. 
The development of chemical target agents that exploit dif-
ferences between cancerous and normal cells permits greater 
specificity for cancer cells with less damage to normal healthy 
cells.34 Although chemotherapy and radiation therapy can 
induce cancer remission in patients with tumors, a group of 
malignancies remains a therapeutic challenge due to frequent 
tumor relapse and chemotherapy resistance.35 Thus, there is a 
continual need to identify drugs which are nontoxic, have few 
adverse side effects, and might be of great benefit in reducing 
the dosage of existing chemotherapeutic drugs.
Doxorubicin is one of the best drugs for systemic chemo-
therapy which works against breast cancer. For colon cancer 
treatment, oxaliplatin is commonly used, while tamoxifen is 
the most commonly used drug for liver cancer.33,35
The evidence currently available clearly indicates that sul-
fated zirconia nanoparticles are toxic in vitro for several types 
of cancer cells including human colorectal carcinoma HT29 
cells, human liver carcinoma HepG2 cells, and human breast 
carcinoma MCF-7 cells. In contrast, normal (noncancerous) 
human breast carcinoma MCF-10a cells were found to be the 
least sensitive to sulfated zirconia nanoparticles.36
As far as it is known, the present in vitro study is the first 
report to determine the anticancer properties of iron–man-
ganese-doped sulfated zirconia nanoparticles. The addition 
of iron will help the directed delivery (via magnetic force) 
of nanoparticles to cancer sites. Iron(+3)–manganese-doped 
sulfated zirconia nanoparticles were synthesized in this study 
via a hydrothermal impregnation method and were character-
ized using X-ray photoelectron spectroscopy, X-ray diffrac-
tion (XRD), thermogravimetric analysis, Fourier transform 
infrared spectroscopy, BET, X-ray fluorescence, zeta size 
potential, and transmission electron microscopy (TEM). The 
toxicity of iron–manganese-doped sulfated zirconia nanopar-
ticles was assessed here against human colon cancer HT29 
cells, human breast cancer MDA-MB231 cells, and human 
liver cancer HepG2 cells in comparison with oxaliplatin, 
doxorubicin, and tamoxifen, respectively. Normal (noncan-
cerous) human liver Chang cells and normal human umbilical 
vein endothelial cells (HUVECs) were used as controls.
The results, coupled with in vitro assays, demonstrate 
much promise for the use of iron(+3)–manganese-doped 
sulfated zirconia nanoparticles in numerous anticancer 
applications.
Materials and methods
chemicals and reagents
Ammonium sulfate, zirconium oxynitrate, and ammonium 
hydroxide (28%–30%) were obtained from Sigma-Aldrich Co. 
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(St Louis, MO, USA). The trypsin/ethylenediaminetetraa-
cetic acid (EDTA) solution was purchased from Thermo 
Fisher Scientific (Waltham, MA, USA). Dimethyl sulfoxide 
(DMSO), phosphate-buffered saline, 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT), Dulbecco’s 
Modified Eagle’s Medium (DMEM), 95% ethanol, fetal 
bovine serum (FBS), trypan blue dye solution, trypsin/EDTA, 
and antibiotics were purchased from Sigma-Aldrich Co.
Preparation of iron(III) oxide–manganese 
dioxide-doped sulfated zirconia and 4%  
sO4
2-
The iron–manganese-doped sulfated zirconia was prepared 
via a precipitation and hydrothermal impregnation method. 
Initially, 5 g of hydrated zirconium nitrate was dissolved in 
approximately 150 mL of deionized water with a dropwise 
addition of 3.0 g of 30% ammonia in 5 mL of deionized water 
which resulted in the precipitation. A necessary amount of 
a 30% ammonia solution was added in order to maintain a 
pH value in the range of 9 to 10. The precipitate was aged 
for 24 hours, filtered by a vacuum pump, and washed with 
approximately 600 mL of warm deionized water. The precipi-
tate was then dried for approximately 18 hours at 120°C.37
Hydrated iron(III) nitrate (0.60 g), tetrahydrated man-
ganese nitrate (Mn(NO
3
)
2
⋅4H
2
O) (0.130 g), and (NH
4
)
2
SO
4 
(0.230 g) were dissolved in approximately 150 mL of deion-
ized water. The solution was added dropwise under vigorous 
stirring into a zirconium oxyhydroxide solution. The mixed 
solution was left while stirring at room temperature for 
6 hours and was then transferred to a closed autoclave 
reactor to dry in an oven at 150°C for 24 hours. Finally, 
the product was calcined for 5 hours at 650°C according to 
standard procedures.38,39
Physicochemical properties of iron–
manganese-doped sulfated zirconia-4% 
sO4
2-
X-ray photoelectron spectra were obtained by employing 
a modified AXIS ULTRA DLD (KRATOS) photoelectron 
spectrometer, fully furnished with a hemispherical analyzer. 
For excitation, AlKα (1,486.6 eV) radiation was applied. The 
analyzer functioned in the fixed analyzer transmission mode 
at a pass energy of 40 eV. The X-ray gun was activated at an 
emission current of 4 mA with 15 kV of stepping-up voltage. 
Samples were pretreated under a vacuum (1×10-9 Torr) at 
22±2°C for 2 hours before analysis. The base pressure of the 
analyzer chamber was 1×10-9 Torr; throughout the collection 
of information, the pressure was constant at ,1×10-9 Torr. 
The binding energy matching to C 1s, Zr 3d, Fe 2p, Mn 2p, 
S 2p, and O 1s was determined. All binding energies are 
relative to the C 1s peak, taken as 284.5 eV.
The thermal strength of the iron(III)–manganese-
doped sulfated zirconia-4% SO
4
2- was investigated via a 
Mettler Toledo TGA-SDTA apparatus (Pt crucibles, Pt/Pt– 
Rh thermocouple), with a purge gas (nitrogen) flow rate of 
30 mL min-1 and a heating rate of 10°C min-1 from room 
temperature to 1,000°C.
To determine functional groups on the surface of the 
iron(III)–manganese-doped sulfated zirconia-4% SO
4
2-, 
Fourier transform infrared analysis was performed with a 
PerkinElmer model 100 series spectrometer.
The total surface area of the iron(III)–manganese-promoted 
sulfated zirconia-4% SO
4
2- was evaluated via nitrogen 
adsorption at -196°C. The evaluation was performed using 
a Thermo Fisher Scientific (model: Surfer analyzer) nitrogen 
adsorption–desorption analyzer.
X-ray fluorescence has been widely accepted as a 
nondestructive method used for identifying and assessing the 
amount of metal or metal oxides incorporated in powders. 
Metallic materials should be transformed into a powder to 
yield an identical shape, while substances with fine particles 
should be compressed to establish the size of the particles 
and pressed into tablets for analysis.
Powder XRD characterization was performed utilizing 
a Shimadzu diffractometer (model XRD 6000). A diffrac-
tometer employing Cu-Kα radiation generated by a Philips 
glass diffraction X-ray tube broad focus 2.7 kW type was 
used at ambient temperature. The crystallite size (T) of the 
samples was calculated by the Debye–Scherrer relationship 
according to standard procedures:40–42
 T =0.9 λ/(β cos θ), (1)
where λ is the incident X-ray wavelength, β is the full width 
at half-maximum, and θ is the diffraction angle.
TEM (Hitachi H-7100) was employed to determine the 
inner finer structure of the crystal. For TEM analysis, the 
powder was disseminated in deionized water, placed onto 
carbon-coated copper grids on a filter paper, and dried at 
room temperature.
The zeta potential of the iron(III)–manganese-doped 
sulfated zirconia nanoparticle dispersions (1 μg of sulfated 
zirconia nanoparticles dispersed in 1 mL of ultra-deionized 
water) was characterized using a Zetasizer Nano ZS instru-
ment (Malvern Instruments, Malvern, UK) with dynamic 
light scattering.
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cell culture
Five human cell lines were obtained from the American 
Type Culture Collection ([ATCC] Manassas, VA, USA). 
The cell lines were MDA-MB231(ATCC® HTB-26™), HT29 
(ATCC® HTB-38™), HepG2 (ATCC® HB-8065™), HUVEC 
(ATCC® CRL-1730™), and Chang (ATCC® CCL-13™), 
which were all characterized as virus-negative. Cells were 
cultured in DMEM supplemented with 10% FBS and 1% 
antibiotics (100 U/mL penicillin) in an incubator at 37°C in 
the presence of 5% CO
2
.
MTT assays
Before applying the iron–manganese-doped sulfated zirconia 
nanoparticles to cell culture, the nanoparticles were well 
distributed in DMEM with 10% heated inactivated FBS 
freshly added using ultrasound treatment in order to obtain 
nanoparticle colloidal suspension. However, according to 
previous studies,36,43 these nanoparticles exhibited stable 
chemical and thermal properties.
MTT assay was performed as previously described.34 In 
brief, cells were plated at a density of 1×104 cells per well by 
adding 200 μL of cell suspension at 5×104 cells/mL into each 
well of a 96-well tissue culture plate. Test compounds were 
added immediately before incubation. Test compounds were 
iron–manganese-doped sulfated zirconia nanoparticles at dif-
ferent concentrations ranging from 7.8 μg/mL to 500 μg/mL 
or the chemotherapeutic agents (oxaliplatin for HT29 cells, 
doxorubicin for MDA-MB231 cells, and tamoxifen for 
HepG2 cells, Chang cells, and HUVECs) at concentrations 
ranging from 0.156 μg/mL to 10.0 μg/mL. The plates were 
incubated at 37°C in the presence of 5% CO
2
 for 72 hours. 
After incubation with compounds, the medium was aspirated 
and cells were washed three times with PBS to ensure that all 
test compounds were removed and then replaced with fresh 
medium. Then, 200 μL of the MTT solution was added to 
every well and incubated for 4 to 6 hours at 37°C with 5% 
CO
2
. The MTT-containing medium was gently removed, 
and replaced with DMSO (200 μL per well) to dissolve the 
formed formazan crystals. The plates were read at 570 nm on 
a microtiter plate reader. For each compound tested, the IC
50 
values (that is, the concentration of drug needed to inhibit cell 
growth by 50%) were determined from the dose–response 
curves for each cell line.
Microscopic examination of cell 
morphology
HepG2 cells, HT29 cells, MDA-MB231 cells, Chang cells, 
and HUVECs (1×104 cells per well) were seeded in six-well 
plates. After cells were exposed to iron–manganese-doped 
sulfated zirconia nanoparticles for 72 hours, at IC
50
 concen-
trations calculated from the MTT results, general cellular 
morphology and membrane changes were examined via a 
light inverted microscope.
All experiments were completed in triplicate and repeated 
at least three different times.
Results and discussion
Figure 1 illustrates the X-ray photoelectron spectra of 
iron(III)–manganese-doped sulfated zirconia-4% SO
4
2-. This 
material exhibited photoelectron lines at 180.7 and 531.5 eV 
attributed to Zr 3d5/2 and oxygen 1s levels, respectively. 
These photoelectron peaks taken together are expected to be 
due to ZrO
2
.44 The higher binding energy species (186.0 eV) 
matched that of Zr4+components attached to the more attrac-
tive species. A total lack of impact on the shape of the Zr 3d 
peak is very significant and suggests the different strengths 
and surroundings of the interfaces between the SO
4
2- species 
and the ZrO
2 
for (NH
4
)
2
SO
4 
hydrothermal impregnation at 
the amount of 4% SO
4
2-.45,46 The S 2p photoelectron lines 
appeared at approximately 168.4 eV (Figure 1C) and indicate 
the presence of sulfur ions (+6) in agreement with the rela-
tive amount to S6+ in sulfates anions and in agreement with a 
previous research article which performed analysis regarding 
sulfate group-doped ZrO
2
 catalysts.46 Figure 1D shows the 
X-ray photoelectron spectrum of iron(3+)–manganese-doped 
sulfated ZrO
2 
in the region of iron 2p. The iron(3+) 2p3/2 
and 2p1/2 photoelectron emissions located at approximately 
711.0 and 723.5 eV, respectively, support the presence of 
Fe
2
O
3 
at the surface of the iron(3+)–manganese-doped sul-
fated ZrO
2
. Moreover, the spectrum is a clear verification of 
the presence of iron(+3) that is almost similar to the Fe
2
O
3
 
spectrum.40,47 Mn photoelectron lines could be distinguished 
only with a rather deprived noisy signal. Figure 1E depicts 
the photoelectron peaks of the iron(3+)–manganese-doped 
sulfated ZrO
2 
substance in the region of the 2p level of Mn. 
Hence, the manganese photoelectron emission of 2p3/2 and 
2p1/2 energy levels was detected at approximately 643.0 and 
652.8 eV, respectively, which confirms the presence of man-
ganese oxide on the surface of iron(3+)–manganese-doped 
SO
4
/ZrO
2
.
Figure 2 displays the thermogravimetric graph of FeMn-
SO
4
/ZrO
2 
and the weight lost, determined from thermogra-
vimetric analysis, which matched well with that estimated 
for the degradation of uncalcined FeMn-SO
4
/ZrO
2
.48 Hence, 
the thermal procedures for uncalcined FeMn-SO
4
/ZrO
2
 
below 600°C were assigned to the removal of physisorbed 
water, a mixture of nitrous oxide gases, and transformation 
processes of zirconyl oxyhydroxide to ZrO
2
. In addition, the 
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second stage of weight loss started approximately 660°C 
and was completed at 950°C, which is attributed to the 
breakdown of the SO
4
2- anions into sulfur dioxide gas.49
Figure 3 shows the Fourier transform infrared spectrum of 
iron(III)–manganese-doped sulfated zirconia-4% SO
4
2-, and, 
accordingly, the existence of sulfate species is recognized 
by the peak which appeared approximately 1,230–1,065 
cm-1, which is attributed to the vibration frequency of both 
the asymmetric and symmetric stretching of the O=S=O and 
O–S–O groups, respectively.50,51 Furthermore, the absence of 
peaks approximately 1,450 cm-1 confirmed the existence 
of polynuclear sulfate in the sample as verified by the absence 
of bands at approximately 1,440 cm-1, whereas the bending 
and stretching of vibration bands of the -OH groups were 
present in the sample, located at approximately 1,625 cm-1 and 
3,325 cm-1, respectively. The manifestation of these peaks in 
spite of high-temperature calcination indicates the presence 
of Brønsted acidic active sites in the surface sample.
The BET surface area as well as the pore-size mea-
surements for the iron(III)–manganese-promoted sulfated 
Figure 1 X-ray photoelectron spectra of iron(+3)–manganese-promoted sulfated zirconia.
Notes: (A) O2- (1s); (B) Zr4+ (3d5/2); (C) Fe3+ (s 2p); (D) for Fe(111) (2p3/2, 2p1/2); and (E) Mn4+ (2p3/2, 2p1/2).
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zirconia-4% SO
4
2- via the BET method were found to be 
57.0 m2/g and 39 nm3, respectively. It was noticed that the 
incorporation of ferric, manganese, and sulfate anions as 
promoters on the surface of ZrO
2 
resulted in an increase in 
BET surface area and the pore size of iron(III)–manganese-
doped sulfated zirconia-4% SO
4
2- samples. This improve-
ment in the physicochemical properties permitted the reacted 
materials to be in proximity of acid sites; hence nanopar-
ticles of iron(III)–manganese-doped sulfated zirconia-4% 
SO
4
2- might have the best activity compared to the sulfated 
zirconia.
The chemical composition of the iron(III)–manganese-
doped sulfated zirconia-4% SO
4
2- sample was determined 
using Shimadzu X-ray fluorescence with a Rayny EDX-720 
spectrometer according to procedures utilized by others.52,53 
The amount of metals and nonmetals incorporated into the 
sample were found to be ferric 1.624%±0.15%, manganese 
0.497%±0.07%, and zirconium 77.7%±0.03%, and the rest 
might have been sulfur and oxygen.
The XRD pattern (as shown in Figure 4) of the iron(III)–
manganese-doped sulfated zirconia-4% SO
4
2- sample 
contained a barely tetragonal zirconia phase located at 
2θ=30.3°, 35.4°, 50.2°, and 60.2° (JCPDS file number 
00-050-10589 – zirconium oxide).54 However, the dif-
fraction line conforming to the monoclinic phase was 
not apparent in the iron(III)–manganese-doped sulfated 
Figure 2 Thermogravimetric analysis–differential temperature curves thermograph of the iron(+3)–manganese-promoted sulfated zirconia sample.
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Figure 3 Fourier transform infrared spectrum of iron(+3)–manganese-promoted sulfated zirconia sample.
Notes: (a) stretching and (b) bending of the Oh group; (c) symmetric stretching of the O–s–O bond; and (d) asymmetric stretching frequency of the O=s=O bond.
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zirconia-4% SO
4
2- XRD pattern, indicating an equilibrium 
in the tetragonal phase in the crystal system. The nonap-
pearance of specific diffraction lines corresponding to 
ferric oxide and manganese dioxide suggests that these 
oxides were well dispersed on the surface of the support. 
The dispersion of ferric oxide and manganese dioxide 
nanoparticles enhanced the equilibrium of the tetragonal 
phase, hence generated higher surface area.55 The size of 
the iron(III)–manganese-doped sulfated zirconia-4% SO
4
2- 
crystal was evaluated using the Debye–Scherrer equation 
and was found to be 12.7 nm.
The shape and size of the crystal and the extent of dis-
persion of iron(III)–manganese-doped sulfated zirconia-4% 
SO
4
2- nanoparticles were examined using TEM. The TEM 
image of iron–manganese-doped sulfated zirconia nano-
particles is displayed in Figure 5. It was obvious that the 
nanoparticle crystals were a nearly tetragonal crystal system 
with sizes ranging from 10.22 to 15.07 nm with an average 
size of 12.5 nm. Moreover, a majority of the iron(III)–
manganese-doped sulfated zirconia-4% SO
4
2- nanoparticles 
agglomerated, while a few were detached.56,57
Zeta potential is a measure of the effective electric 
charge on a nanoparticle surface. The magnitude of the zeta 
potential provides information about particle stability, thus 
zeta potentials exhibiting increased stability due to a larger 
electrostatic repulsion between particles. The zeta potential 
for the Fe3+-Mn4+-SO
4
/ZrO
2 
nanoparticle suspensions was 
found to be 15.0±4.56 mV. This result may indicate that 
Fe3+-Mn4+-SO
4
/ZrO
2 
nanoparticles tend to agglomerate in 
deionized and double-distilled water. It verifies that these 
nanoparticles have low electrostatic repulsion properties 
and incipient instability.
cellular sensitivity of cancer and normal 
cells to iron–manganese-doped sulfated 
zirconia nanoparticles
Three human cancer cell lines, estrogen receptor-negative 
(ER–) MDA-MB-231 cells, colon cancer HT29 cells, and liver 
cancer HepG2 cells, were used to determine the cytotoxicity 
of iron–manganese-doped sulfated zirconia nanoparticles. 
Non-tumorous human liver Chang cells and HUVECs have 
been used as controls in many studies and were chosen here 
to determine the selectivity of our formulated nanoparticles. 
The survival of five human-derived cells after treatment with 
the iron–manganese-doped sulfated zirconia nanoparticles 
and chemotherapeutic agents after 72 hours was determined. 
The responses of cells to increasing concentrations of the 
test compounds are shown in Figure 6. The results showed 
a decreased inhibition of both HepG2 and MDA-MB231 cell 
lines upon low nanoparticle concentrations, with a tapering 
response intensity as the concentrations of nanoparticles 
increased. The MTT assay showed a concentration-dependent 
suppression effect of nanoparticles on cell viability, with 
higher reduction seen in MDA-MB231 cells.
Following 72 hours of incubation with the nanoparticles 
at a concentration of 31 μg/mL, HT29, HepG2, and MDA-
MB-231 cells retained 68%, 55%, and 44% viability, respec-
tively, indicating a decrease in cell growth by 32%, 45%, and 
56% for the HT29, HepG2, and MDA-MB-231 cells, respec-
tively. In contrast, normal human HUVECs and Chang cells 
which were similarly treated with nanoparticles showed a less 
than 7% decrease in growth, thereby retaining 93% viability 
(Figure 6). An insignificant decrease in growth of HUVECs 
as compared to considerably higher values seen in normal 
liver Chang cells indicated that the iron–manganese-doped 
sulfated zirconia nanoparticles exhibited low toxicity toward 
Figure 4 X-ray diffraction pattern of the Fe3+-Mn4+-sO4/ZrO2 sample calcined at 
650°c for 5 hours.
Note: (a) Tetragonal phase of zirconia.
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Figure 5 Transmission electron microscopy image of the Fe3+-Mn4+-sO4/ZrO2 
sample calcined at 650°c for 5 hours.
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normal endothelial cells and significantly higher toxicity 
toward cancer cells and normal liver cells. The IC
50
 values 
of nanoparticles after 72 hours of treatment ranged between 
25 and 50 μg/mL for MDA-MB231 and HepG2 cell lines, 
while it was found to be significantly higher (194 μg/mL) for 
the normal HUVECs (Table 1). The iron–manganese-doped 
sulfated zirconia nanoparticles showed lower IC
50
 values for 
the liver HepG2 (41 μg/mL) cancer cells compared to the 
normal liver Chang cells (95 μg/mL).
These present results suggest that the present nanopar-
ticles may have strong potential as an anticancer agent. These 
findings mirror those of a recent study which demonstrated 
the anticancer potentials of sulfated zirconia nanoparticles on 
the same two cell lines (HT29 and HepG2 cells) following 
similar treatments.36
In liver cancer HepG2 cells and normal liver Chang 
cells, tamoxifen did not show selectivity in targeting cancer 
cells. Tamoxifen, doxorubicin, and oxaliplatin incubation 
resulted in concentration-dependent toxicities on both cancer 
and normal cells. However, the sensitivity of the cells to 
chemotherapies was considerably different.
Morphological examination of treated 
cells
Figure 7 shows that healthy cells remained elongated, whereas 
dying or dead cells became rounded and lost their adhesion to 
culture plates. Inverse microscopy performed after 72 hours 
of challenges to MDA-MB231, HT29, and HepG2 cells with 
the iron–manganese-doped sulfated zirconia nanoparticles 
at 28, 125, and 41 μg/mL, respectively, revealed dramatic 
morphological changes. Cellular extensions were detected; 
cells were rounded and partially detached from the culture 
flask, and cellular membranes showed extensive blebbing, 
especially in both MDA-MB231 and HepG2 cell lines. 
Figure 6 (Continued)
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Table 1 comparison of Ic50 values for hepg2 cells, hT29 cells, MDD-MB231 cells, chang cells, and hUVecs obtained from MTT 
assay following exposure to iron–manganese-promoted sulfated zirconia nanoparticles and chemotherapies for 72 hours
Cells Iron–manganese-promoted sulfated
zirconia nanoparticles (µg/mL)
Chemotherapies
(µg/mL)
hT29 125.31 3.59 (oxaliplatin)
MDa-MB231 28.06 0.27 (doxorubicin)
hepg2 41.26 3.22 (tamoxifen)
chang 95.13 1.19 (tamoxifen)
hUVecs 193.88 2.47 (tamoxifen)
Abbreviations: hUVecs, human umbilical vein endothelial cells; Ic50, concentration of drug needed to inhibit cell growth by 50%; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide.
Figure 6 Iron–manganese-promoted sulfated zirconia NP and chemotherapeutic effects on the viability of treated cells, which were evaluated through mitochondrial activity 
using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay.
Notes: Mean ± standard deviation (n=3 wells/treatment). *P,0.05 compared with the untreated cells.
Abbreviations: hUVec, human umbilical vein endothelial cell; NP, nanoparticle.
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In fact, incubation with the iron–manganese-doped sulfated 
zirconia nanoparticles resulted in a deterioration of the 
monolayer and loosening of colon cancer HT29 cells less 
than that seen in other cancer cell lines. The normal liver 
Chang cells had lost their normal flat morphology and had 
become spherical. Iron–manganese-doped sulfated zirco-
nia nanoparticle treatment, at 95 μg/mL and 193 μg/mL, 
caused drastic changes in both normal Chang cells and 
HUVECs, respectively. Some normal cells retained their 
normal shape and formed a monolayer. After treatment with 
iron–manganese-promoted sulfated zirconia nanoparticles, 
the HT29 cells were more confluent and adherent to their 
surface than HepG2 and MDA-MB231 cells (Figure 7).
Conclusion
This study shows that the prepared ferric (III)– manganese- 
promoted sulfated zirconia nanoparticles possessed advanced 
physicochemical properties. The magnitude of the zeta poten-
tial indicates that the low degree of electrostatic repulsion 
conferred its low stability. The MTT and morphological 
assays used to evaluate the cytotoxicity of iron–manganese-
doped sulfated zirconia nanoparticles against HepG2 and 
MDA-MB-231 cell lines showed that the nanoparticles were 
significantly cytotoxic to these cells in a dose-dependent 
manner, and considerably less cytotoxic toward normal 
Chang cells and HUVECs. Human colon cancer HT29 cells 
showed the highest resistance to the nanoparticles among 
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Figure 7 The morphological changes of hepg2 cells, hT29 cells, MDD-MB231 cells, chang cells, and hUVecs treated with iron–manganese-promoted sulfated zirconia 
nanoparticles at their respective Ic50 concentrations for 72 hours..
Abbreviations: hUVec, human umbilical vein endothelial cell; Ic50, concentration of drug needed to inhibit cell growth by 50%; NPs, nanoparticles.
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tested cancer cells. These findings highlight the potential of 
iron–manganese-doped sulfated zirconia nanoparticles in 
the treatment of cancer. However, there is a need to study 
their effect in vivo to ascertain whole-body efficacy and/or 
any side effects.
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